Spanish HTA organization Institute of Health Carlos III has published an evaluation report on therapeutic efficacy and safety of hyperbaric oxygen therapy

16

Mar 2018

Hyperbaric oxygen therapy (HBOT) is a non-invasive treatment based on the usage of pure oxygen in order to achieve the particular level of pressure. It is used for the treatment of tissue hypoxia via an increase in the transport of plasmatic oxygen in patients with Complex Regional Pain Syndrome (CRPS). This therapy is not widely spread in Spain since there are few centers with hyperbaric medicine, as well as the high economic burden of the procedure.

The Institute has developed a systematic literature review, based on 15 articles, including HTA reports, RCTs, other systematic reviews and clinical guidelines.

The key conclusions of the AETS systematic literature review are listed below:

  • HBOT-therapy demonstrates a significant therapeutic effect but without sufficient sample size to support the results from that point of view;
  • As a non-invasive treatment, HBOT-technology is a very promising method that represents a safe, well-tolerated and feasible management for CRPS;
  • When combined with other rehabilitation therapies for vascular contraction-vasodilation (contrast baths), HBOT can be used to reduce the recovery time;
  • However, it is crucial to conduct more extensive clinical trials to improve HBOT-protocols;
  • Due to the accessibility issues, it is not necessary to increase the number of new facilities but to improve access to the existing ones;
  • It is recommended to provide access to technology in the public settings and obtain agreements with insurance companies for the provision of HBOT in private settings.

See the full report in Spanish with English summary here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more